EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

被引:0
|
作者
Jonathan Gear
Carlo Chiesa
Michael Lassmann
Pablo Mínguez Gabiña
Johannes Tran-Gia
Caroline Stokke
Glenn Flux
机构
[1] Joint Department of Physics,Nuclear Medicine
[2] Royal Marsden Hospital & Institute of Cancer Research,Department of Nuclear Medicine
[3] Foundation IRCCS Istituto Nazionale Tumori,Department of Medical Physics and Radiation Protection
[4] University of Würzburg,Department of Diagnostic Physics, Division of Radiology and Nuclear Medicine
[5] Gurutzeta/Cruces University Hospital,undefined
[6] Oslo University Hospital,undefined
来源
关键词
Dosimetry; Molecular radiotherapy; Iodine-131; mIBG; Neuroendocrine; Neuroblastoma;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of the EANM Dosimetry Committee Series on “Standard Operational Procedures for Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of 131I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.
引用
收藏
相关论文
共 50 条
  • [41] Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
    Genolla, Jose
    Rodriguez, Trinidad
    Minguez, Pablo
    Lopez-Almaraz, Ricardo
    Llorens, Veronica
    Echebarria, Aizpea
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (07) : 1567 - 1575
  • [42] Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results
    Giostra, A.
    Richetta, E.
    Pasquino, M.
    Miranti, A.
    Cutaia, C.
    Brusasco, G.
    Pellerito, R. E.
    Stasi, M.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2016, 61 (11): : 4316 - 4326
  • [43] Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
    Jose Genolla
    Trinidad Rodriguez
    Pablo Minguez
    Ricardo Lopez-Almaraz
    Veronica Llorens
    Aizpea Echebarria
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1567 - 1575
  • [44] Treatment planning for 131I-mIBG Radionuclide therapy of high-risk neuroblastoma based on patient-specific Dosimetry
    Buckley, S.
    Saran, F.
    Gaze, M.
    Hindorf, C.
    Chittenden, S.
    Lancaster, D.
    Pearson, A.
    Flux, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S179 - S179
  • [45] Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma
    Huang, Shih-ying
    Bolch, Wesley E.
    Lee, Choonsik
    Van Brocklin, Henry F.
    Pampaloni, Miguel H.
    Hawkins, Randall A.
    Sznewajs, Aimee
    DuBois, Steven G.
    Matthay, Katherine K.
    Seo, Youngho
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (02) : 284 - 294
  • [46] Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma
    Shih-ying Huang
    Wesley E. Bolch
    Choonsik Lee
    Henry F. Van Brocklin
    Miguel H. Pampaloni
    Randall A. Hawkins
    Aimee Sznewajs
    Steven G. DuBois
    Katherine K. Matthay
    Youngho Seo
    [J]. Molecular Imaging and Biology, 2015, 17 : 284 - 294
  • [47] Dosimetry studies for the clinical transfer of targeted radiotherapy with [131I]ICF01012 for pigmented melanoma metastases treatment.
    Degoul, F.
    Perrot, Y.
    Viallard, C.
    Jouberton, E.
    Valla, C.
    Millardet, C.
    Maigne, L.
    Chezal, J.
    Miot-Noirault, E.
    Cachin, F.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S281 - S281
  • [48] Red marrow dosimetry in 131I treatment of metastatic differentiated thyroid carcinoma: pre-treatment versus on-therapy preliminary results
    Richetta, E.
    Giostra, A.
    Gino, E.
    Pellerito, R. E.
    Stasi, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S255 - S256
  • [49] Dosimetry of regressing tumors in 131I internal emitter therapy using patient data from multiple, integrated CT-SPECT imagesi
    Wilderman, Scott J.
    Dewaraja, Yuni K.
    [J]. 2007 IEEE NUCLEAR SCIENCE SYMPOSIUM CONFERENCE RECORD, VOLS 1-11, 2007, : 3660 - 3664
  • [50] Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning
    Pettinato, Cinzia
    Spezi, Emiliano
    Nanni, Cristina
    Grassetto, Gaia
    Monari, Fabio
    Allegri, Vincenzo
    Civollani, Simona
    Cima, Simona
    Zagni, Paolo
    Mazzarotto, Renzo
    Colletti, Patrick M.
    Rubello, Domenico
    Fanti, Stefano
    [J]. CLINICAL NUCLEAR MEDICINE, 2014, 39 (08) : E367 - E374